SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934
Date of report: March 24, 2010
(Date of earliest event reported)
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number : 1-7928
(State or other jurisdiction of
incorporation or organization)
1000 Alfred Nobel Drive
Hercules, California 94547
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 24, 2010, Bio-Rad Laboratories, Inc. (the Company) appointed Ted. W. Love, M.D. to its Board of Directors and as a member of the Boards audit committee. He replaced Mr. Ruediger Naumann-Etienne who resigned on December 4, 2009. Dr. Love will stand for election to the Board along with the Companys other directors at the Companys annual meeting of stockholders on April 27, 2010. There is no arrangement or understanding pursuant to which Dr. Love was appointed as director.
On the same basis as the other non-employee directors of the Company, Dr. Love will be entitled to receive a fee of $2,000 per month plus an additional $100 per board meeting for any meetings in excess of 16 per year. In addition, Dr. Love will be entitled to receive an additional $625 per month for serving on the audit committee.
As a result of Dr. Loves appointment, the Company regained compliance with the requirements of Section 303.A.07(a) of the New York Stock Exchange (NYSE) Listed Company Manual, which requires a listed company to have three independent directors on its audit committee. On March 25, 2010, the Company received written notice from the NYSE acknowledging that the Company is in compliance with all NYSE corporate governance listing standards. As a result, the BC or below compliance indicator, which was previously placed on the Companys ticker symbol subsequent to Mr. Naumann-Etiennes resignation, was removed on March 26, 2010.
Financial Statements and Exhibits
Press release of Bio-Rad Laboratories, Inc. dated March 25, 2010
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-RAD LABORATORIES, INC.
March 29, 2010
/s/ Christine A. Tsingos
Christine A. Tsingos
Vice President, Chief Financial Officer